P M Loadman

Summary

Affiliation: University of Bradford
Country: UK

Publications

  1. ncbi request reprint Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
    P M Loadman
    Clinical Oncology Unit, University of Bradford, UK
    Biochem Pharmacol 59:831-7. 2000
  2. ncbi request reprint Separation methods for anthraquinone related anti-cancer drugs
    P M Loadman
    Cancer Research Unit, University of Bradford, UK
    J Chromatogr B Biomed Sci Appl 764:193-206. 2001
  3. ncbi request reprint Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1
    P M Loadman
    Clinical Oncology Unit, University of Bradford, United Kingdom
    Clin Cancer Res 5:3682-8. 1999
  4. ncbi request reprint Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development
    R M Phillips
    Cancer Research Unit, University of Bradford, United Kingdom
    Cancer Res 60:6384-90. 2000
  5. pmc Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
    R M Phillips
    Clinical Oncology Unit, University of Bradford, UK
    Br J Cancer 77:2112-9. 1998
  6. pmc Pre-clinical evaluation of a novel chloroethylating agent, Clomesone
    A M Matthew
    Clinical Oncology Unit, University of Bradford, West Yorkshire, UK
    Br J Cancer 67:441-6. 1993
  7. pmc Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice
    M C Bibby
    Clinical Oncology Unit, University of Bradford, UK
    Br J Cancer 65:347-50. 1992
  8. ncbi request reprint Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours
    M C Bibby
    School of Clinical Oncology, University of Bradford, West Yorks, UK
    Cancer Chemother Pharmacol 20:203-6. 1987
  9. pmc Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512)
    M C Bibby
    Clinical Oncology Unit, University of Bradford
    Br J Cancer 58:341-4. 1988
  10. ncbi request reprint A preclinical pharmacokinetic study of the bioreductive drug AQ4N
    P M Loadman
    Cancer Research Unit, University of Bradford, Bradford, United Kingdom
    Drug Metab Dispos 29:422-6. 2001

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
    P M Loadman
    Clinical Oncology Unit, University of Bradford, UK
    Biochem Pharmacol 59:831-7. 2000
    ..8 microM). The two DTD substrates RH1 and EO9 are clearly metabolised differently, suggesting that RH1 may have different pharmacological properties to those of EO9 in the clinic...
  2. ncbi request reprint Separation methods for anthraquinone related anti-cancer drugs
    P M Loadman
    Cancer Research Unit, University of Bradford, UK
    J Chromatogr B Biomed Sci Appl 764:193-206. 2001
    ..The methods described are used for sometimes complex separations that are needed for the evaluation of such compounds in biological samples...
  3. ncbi request reprint Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1
    P M Loadman
    Clinical Oncology Unit, University of Bradford, United Kingdom
    Clin Cancer Res 5:3682-8. 1999
    ..These studies are likely to have clinical implications as aggressive tumors are known to have increased protease activity...
  4. ncbi request reprint Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development
    R M Phillips
    Cancer Research Unit, University of Bradford, United Kingdom
    Cancer Res 60:6384-90. 2000
    ....
  5. pmc Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
    R M Phillips
    Clinical Oncology Unit, University of Bradford, UK
    Br J Cancer 77:2112-9. 1998
    ..These results suggest that the failure of EO9 in the clinic is due to a combination of poor drug penetration and rapid elimination in vivo...
  6. pmc Pre-clinical evaluation of a novel chloroethylating agent, Clomesone
    A M Matthew
    Clinical Oncology Unit, University of Bradford, West Yorkshire, UK
    Br J Cancer 67:441-6. 1993
    ..It was concluded that this study found no evidence to suggest that Clomesone was toxicologically more selective than the chloroethylnitrosoureas...
  7. pmc Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice
    M C Bibby
    Clinical Oncology Unit, University of Bradford, UK
    Br J Cancer 65:347-50. 1992
    ..It is likely that the increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when administered with hydralazine, but the impact of these findings on toxicity needs to be established...
  8. ncbi request reprint Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours
    M C Bibby
    School of Clinical Oncology, University of Bradford, West Yorks, UK
    Cancer Chemother Pharmacol 20:203-6. 1987
    ..The therapeutic effects of ThioTEPA cannot be predicted purely from a knowledge of drug and metabolite disposition...
  9. pmc Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512)
    M C Bibby
    Clinical Oncology Unit, University of Bradford
    Br J Cancer 58:341-4. 1988
    ..The unique chemosensitivity of MAC 16 to FAA suggests that this agent has a novel mechanism which may be dependent upon specific biological characteristics of tumours...
  10. ncbi request reprint A preclinical pharmacokinetic study of the bioreductive drug AQ4N
    P M Loadman
    Cancer Research Unit, University of Bradford, Bradford, United Kingdom
    Drug Metab Dispos 29:422-6. 2001
    ..The concentrations necessary for a therapeutic response in vivo have been described in this pharmacokinetic study...
  11. pmc Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9
    P M Loadman
    Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford BD7 1DP
    Br J Pharmacol 137:701-9. 2002
    ....
  12. ncbi request reprint Comet assay and flow cytometry analysis of DNA repair in normal and cancer cells treated with known mutagens with different mechanisms of action
    M Suggitt
    Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom
    Teratog Carcinog Mutagen . 2003
    ..Also, at the highest mutagen doses there were different patterns of micronuclei induction. Thus, using the mutagens with different mechanisms of action highlighted the differences in repair patterns between normal and tumour cells...
  13. ncbi request reprint Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity
    J M Atkinson
    Institute of Cancer Therapeutics, University of Bradford, Tumbling Hill Street, Bradford, West Yorkshire, BD7 1DP, UK
    Eur J Cancer 43:1764-71. 2007
    ..These data suggest that MMP-14, -15 and -17 may be good markers of disease, or therapeutic targets for treatment of human NSCLC...